misleading statements

Rosen Law Firm filed class action against Aquestive Therapeutics alleging false statements about product development and regulatory matters. Eligible investors should act before deadline.

Class action lawsuit filed against $CWH for allegedly making false statements about business operations. Stock fell 24.8% and 16.5% in two separate drops.

Class action lawsuit filed against Mereo BioPharma over alleged misstatements regarding failed Phase 3 clinical trials. Investors have until April 6, 2026, to join.

Class action lawsuit filed against $CORP alleging executives made false statements about relacorilant's clinical strength and FDA approval prospects.

Navan Inc. faces securities lawsuit over undisclosed marketing expenses. Stock tumbled 60% since October offering; investors have until April 24, 2026 to join class action.

Snowflake Inc. faces securities class action lawsuit alleging false statements about product efficiency and features. Lead plaintiff deadline set for April 27, 2026.

Class action lawsuit filed against $CWH alleging false statements about inventory management capabilities, claiming misleading public disclosures harmed shareholders.

REGENXBIO faces securities lawsuit over alleged misleading RGX-111 gene therapy statements. Lead plaintiff deadline is April 14, 2026.

Portnoy Law Firm files class action against Camping World Holdings for materially false statements regarding inventory management and consumer demand between April 2025 and February 2026.

Class action lawsuit filed against Camping World Holdings alleges false inventory management claims and financial misstatements from April 2025 to February 2026.

Class action filed against Ultragenyx ($RARE) alleging misrepresented setrusumab trial data. Investors purchasing August 2023-December 2025 may recover damages.

Corcept Therapeutics faces securities class action over allegedly misleading statements about relacorilant's FDA approval prospects, triggering 50% stock plunge and $3.6B market cap loss.

Camping World Holdings faces class action lawsuit over alleged false statements about inventory management. Stock fell 25% after Q3 earnings, then 16% after Q4 results; dividend suspended.

Rosen Law Firm files securities class action against $AQST over alleged misleading statements regarding its Anaphylm drug application between June 2025 and January 2026.

Law firm Bragar Eagel & Squire files class action lawsuits against $NAVAN and $COPT alleging material misstatements, citing 60%+ and 50%+ stock declines respectively.

Class action lawsuits filed against $SMR developer NuScale and $OSTN over securities fraud, including $110M scheme and misrepresented nuclear partnerships.

monday.com faces class action lawsuit alleging false growth projections during 2025-2026 period. Stock fell 21% after company abandoned $1.8B 2027 revenue target.

Law firm investigates $BSC for allegedly misleading investors about U.S. Electrophysiology growth sustainability and competitive pressures during July 2025-February 2026 period.

Boston Scientific faces class action lawsuit alleging misleading statements about electrophysiology market position, with stock down 17% after missing earnings guidance.

Class action filed against Ramaco Resources ($METC) alleging executives made false statements about Brook Mine development progress, affecting investors from July-October 2025.